Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75-10.05, p=5.41×10−7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.
Author Summary COVID-19 clinical outcomes vary immensely, but a patient’s genetic make-up is an important determinant of how they will fare against the virus. While many genetic variants commonly found in the populations were previously found to be contributing to more severe disease by the COVID-19 Host Genetics Initiative, it isn’t clear if more rare variants found in less individuals could also play a role. This is important because genetic variants with the largest impact on COVID-19 severity are expected to be rarely found in the population, and these rare variants require different technologies to be studies (usually whole-exome or whole-genome sequencing). Here, we combined sequencing results from 21 cohorts across 12 countries to perform a rare variant association study. In an analysis comprising 5,085 participants with severe COVID-19 and 571,737 controls, we found that the gene for toll-like receptor 7 (TLR7) on chromosome X was an important determinant of severe COVID-19. Importantly, despite being found on a sex chromosome, this observation was consistent across both sexes.
Competing Interest Statement
See Suppl. Table 2.
Funding Statement
See Suppl. Tables 2-4.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
See Suppl. Table 1-2.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: See Suppl. Tables 2-3.
Disclosures: See Supp. Tables 2-3.
Additional sex and ancestry stratified analyses. Bug fixes.
Data Availability
The exome-wide burden test summary statistics are available in the Supplements. The single variant association studies summary statistics will be made available openly on the GWAS Catalog following publication.
Subject Area
- Addiction Medicine (347)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2642)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12213)
- Forensic Medicine (10)
- Gastroenterology (758)
- Genetic and Genomic Medicine (4089)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2650)
- Health Policy (1004)
- Hematology (362)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3867)
- Nursing (209)
- Nutrition (577)
- Oncology (2025)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6518)
- Radiology and Imaging (1399)
- Respiratory Medicine (871)
- Rheumatology (406)
- Sports Medicine (342)
- Surgery (446)
- Toxicology (53)
- Transplantation (185)
- Urology (165)